CN106999458B - 用于预防和治疗糖尿病的经取代芳族化合物和药物组合物 - Google Patents

用于预防和治疗糖尿病的经取代芳族化合物和药物组合物 Download PDF

Info

Publication number
CN106999458B
CN106999458B CN201580066107.9A CN201580066107A CN106999458B CN 106999458 B CN106999458 B CN 106999458B CN 201580066107 A CN201580066107 A CN 201580066107A CN 106999458 B CN106999458 B CN 106999458B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
diabetes
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580066107.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106999458A (zh
Inventor
L·加尼翁
B·格劳克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biosciences Inc
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of CN106999458A publication Critical patent/CN106999458A/zh
Application granted granted Critical
Publication of CN106999458B publication Critical patent/CN106999458B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580066107.9A 2014-10-10 2015-10-08 用于预防和治疗糖尿病的经取代芳族化合物和药物组合物 Expired - Fee Related CN106999458B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062526P 2014-10-10 2014-10-10
US62/062526 2014-10-10
PCT/CA2015/000531 WO2016054726A1 (en) 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

Publications (2)

Publication Number Publication Date
CN106999458A CN106999458A (zh) 2017-08-01
CN106999458B true CN106999458B (zh) 2021-04-13

Family

ID=55652427

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580066107.9A Expired - Fee Related CN106999458B (zh) 2014-10-10 2015-10-08 用于预防和治疗糖尿病的经取代芳族化合物和药物组合物

Country Status (21)

Country Link
US (1) US10105331B2 (enExample)
EP (1) EP3203998B1 (enExample)
JP (1) JP6676629B2 (enExample)
KR (1) KR20170066614A (enExample)
CN (1) CN106999458B (enExample)
AR (1) AR102248A1 (enExample)
AU (1) AU2015330643B2 (enExample)
BR (1) BR112017007420A2 (enExample)
CA (1) CA2963276A1 (enExample)
DK (1) DK3203998T3 (enExample)
ES (1) ES2875336T3 (enExample)
IL (1) IL251392B (enExample)
MX (1) MX376872B (enExample)
PH (1) PH12017500662B1 (enExample)
PL (1) PL3203998T3 (enExample)
PT (1) PT3203998T (enExample)
RU (1) RU2723486C2 (enExample)
SG (1) SG11201702812PA (enExample)
TW (1) TWI699201B (enExample)
UY (1) UY36354A (enExample)
WO (1) WO2016054726A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
CA2967499C (en) * 2014-11-12 2023-01-17 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
CN120923343A (zh) 2018-10-11 2025-11-11 巴斯夫股份公司 芳族化合物及其医药用途
JP2024512510A (ja) * 2020-10-06 2024-03-19 ファーマセウティーク・インジェニュー・インコーポレイテッド 置換芳香族化合物及びその医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031931A2 (en) * 2004-09-15 2006-03-23 The President And Fellows Of Harvard College Reducing er stress in the treatment of obesity and diabetes
WO2014138906A1 (en) * 2013-03-15 2014-09-18 Prometic Biosciences Inc. Substituted aromatic compounds and related method for the treatment of fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
BRPI0407506A (pt) * 2003-02-13 2006-02-14 Wellstat Therapeutics Corp compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos
AT509045B1 (de) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
JP2012072136A (ja) * 2010-09-03 2012-04-12 Erina Co Inc 細胞内代謝促進用組成物、その組成物を含有する糖代謝又は脂質代謝疾患の予防及び／又は治療用医薬製剤、機能性食品及び健康食品
US20130225683A1 (en) * 2010-10-27 2013-08-29 Prometic Biosciences Inc. Compounds and Pharmaceutical Compositions for Uses in Diabetes
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031931A2 (en) * 2004-09-15 2006-03-23 The President And Fellows Of Harvard College Reducing er stress in the treatment of obesity and diabetes
WO2014138906A1 (en) * 2013-03-15 2014-09-18 Prometic Biosciences Inc. Substituted aromatic compounds and related method for the treatment of fibrosis

Also Published As

Publication number Publication date
PH12017500662A1 (en) 2017-10-02
WO2016054726A1 (en) 2016-04-14
CA2963276A1 (en) 2016-04-14
JP2017530182A (ja) 2017-10-12
EP3203998A4 (en) 2018-06-20
RU2017116106A (ru) 2018-11-12
EP3203998A1 (en) 2017-08-16
MX2017004738A (es) 2017-08-10
JP6676629B2 (ja) 2020-04-08
PT3203998T (pt) 2021-06-07
SG11201702812PA (en) 2017-05-30
PH12017500662B1 (en) 2022-08-19
US20170209399A1 (en) 2017-07-27
IL251392B (en) 2020-11-30
IL251392A0 (en) 2017-05-29
RU2723486C2 (ru) 2020-06-11
BR112017007420A2 (pt) 2018-01-16
AU2015330643B2 (en) 2020-05-14
AR102248A1 (es) 2017-02-15
EP3203998B1 (en) 2021-03-10
TW201618763A (zh) 2016-06-01
PL3203998T3 (pl) 2021-09-27
MX376872B (es) 2025-03-07
TWI699201B (zh) 2020-07-21
UY36354A (es) 2016-06-01
RU2017116106A3 (enExample) 2019-02-13
CN106999458A (zh) 2017-08-01
DK3203998T3 (da) 2021-05-31
AU2015330643A1 (en) 2017-05-04
US10105331B2 (en) 2018-10-23
ES2875336T3 (es) 2021-11-10
KR20170066614A (ko) 2017-06-14

Similar Documents

Publication Publication Date Title
US20130225683A1 (en) Compounds and Pharmaceutical Compositions for Uses in Diabetes
EP4125896B1 (en) Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
KR20160003794A (ko) 상승적 조성물
CN106999458B (zh) 用于预防和治疗糖尿病的经取代芳族化合物和药物组合物
TWI846843B (zh) 適用於治療高血糖症的雜環基(苯基)甲醇化合物
US9499467B2 (en) Ortho-fluoro substituted compounds for the treatment of metabolic diseases
KR20020012220A (ko) 신규한 디페닐에틸렌 화합물
US20210053938A1 (en) Compounds containing carbon-carbon linker as gpr120 agonists
JP6412241B2 (ja) 肝機能改善法
KR100682696B1 (ko) 당뇨병 치료제
CA2598491A1 (en) Diastereoisomers of 4-hydroxyisoleucine and uses thereof
HK1236421B (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
WO2011075935A1 (zh) 二苯基乙烯类衍生物及其用途
KR20100107469A (ko) 당뇨병 치료용 옥타하이드로퀴놀리진
US20250223296A1 (en) Hydroxymethyl azabicyclo[2.2.1]heptanes and medical uses thereof
ZA200500914B (en) Indoles having anti-diabetic activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210413

CF01 Termination of patent right due to non-payment of annual fee